Marizomib May Be Effective In Relapsed / Refractory Multiple Myeloma (ASH 2011)
Combined data from two recent Phase 1 clinical trials suggest that twice-weekly marizomib, with or without low-dose dexamethasone, may be effective for patients with relapsed or refractory multiple...
View ArticleExperts Publish Consensus Statement On Maintenance Therapy In Multiple Myeloma
A group of myeloma experts from the International Myeloma Working Group recently published a consensus statement on maintenance therapies for myeloma patients. In their statement, the experts reviewed...
View ArticlePerifosine Combination May Be Effective In Relapsed/Refractory Multiple...
The final results of a Phase 1/2 clinical trial indicate that perifosine in combination with Velcade and dexamethasone may be effective in multiple myeloma patients who previously relapsed from or...
View ArticleSequence Of Velcade And Revlimid Treatment May Not Matter In Many Multiple...
The results of a recent retrospective analysis show that the sequence of treatment with Velcade and Revlimid may not have a significant effect on outcomes in multiple myeloma patients. Only patients...
View ArticleHigh-Risk Myeloma Patients With Trisomies May Not Be High Risk After All
Results of a recent study suggest that high-risk multiple myeloma patients who have chromosomal abnormalities known as trisomies have better survival outcomes than high-risk patients without them. “Our...
View ArticleStudy Finds Donor Lymphocyte Infusions Are More Effective When Used...
Results of a recent retrospective analysis suggest that donor lymphocyte infusions appear to work better when they are used in patients who have residual multiple myeloma than in those who have...
View ArticleCurcumin May Reduce Free Light Chains In Patients With MGUS And Smoldering...
Results of a small Australian study show that patients with the myeloma precursor diseases monoclonal gammopathy of undetermined significance and smoldering multiple myeloma experienced reduced levels...
View ArticleNew Multiple Myeloma Treatments On The Horizon (ASCO 2012)
During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), results will be presented from clinical trials involving potential new drugs under development for the treatment...
View ArticleASCO 2012 Multiple Myeloma Update – Day Four: Poster Presentations On Various...
Today is the last day of this year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago. However, the multiple myeloma-related presentations at the meeting...
View ArticleDaratumumab Shows Promise As Treatment For Relapsed / Refractory Multiple...
Interim results of an ongoing early-stage clinical trial indicate that daratumumab is safe as a treatment for relapsed and refractory multiple myeloma. In addition, daratumumab showed promising...
View ArticleElotuzumab Combination Continues To Show Promise As Treatment For Multiple...
Elotuzumab in combination with Revlimid and dexamethasone continues to show promise in relapsed and refractory myeloma patients, according to updated results from an ongoing Phase 2 clinical trial....
View ArticleMyeloma Research To Be Presented At The European Hematology Association’s...
Multiple myeloma physicians and researchers are gathering at the 17th Congress of the European Hematology Association (EHA) to share the latest findings in the field. The meeting started today in...
View ArticleMLN9708 Shows Encouraging Results For The Treatment Of Multiple Myeloma (ASCO...
Interim results from three clinical trials suggest that MLN9708, as a single agent or in combination with Revlimid and dexamethasone, may be an effective and well tolerated treatment for both...
View ArticleCyclophosphamide-Thalidomide-Dexamethasone May Deepen Responses After Stem...
Results from a small British Phase 2 study suggest that therapy with a combination of cyclophosphamide, thalidomide, and dexamethasone may deepen multiple myeloma patients’ responses after stem cell...
View ArticleStem Cell Transplants May Increase Risk Of Heart Disease
Results from a large, retrospective study conducted at City of Hope National Medical Center indicate that patients who receive stem cell transplants are at a higher risk of developing heart disease...
View ArticleResearchers Develop Vulnerability Score To Better Assess Survival In Multiple...
Italian researchers have developed a vulnerability score to better assess survival in multiple myeloma patients. The score is based on the patient’s overall health and the presence of other diseases....
View ArticleKidney Transplants: Should More Multiple Myeloma Patients Receive Them?
Researchers from the United Kingdom recently published a review in which they assess the role of kidney transplantation in multiple myeloma. The authors conclude that, for certain multiple myeloma...
View ArticleSecond Transplant May Be An Effective And Safe Salvage Therapy For Certain...
Findings from a recent retrospective study indicate that a second autologous stem cell transplant may be an effective and safe salvage therapy for certain relapsed and refractory multiple myeloma...
View ArticleTabalumab Plus Velcade Shows Therapeutic Benefit In Previously Treated...
Results from a Phase 1 study indicate that tabalumab in combination with Velcade demonstrates both efficacy and safety in myeloma patients who have relapsed after several previous therapies. Dr. Nooper...
View ArticleDaratumumab Continues To Show Promise For Relapsed/Refractory Myeloma...
Daratumumab continues to show promise for relapsed and refractory multiple myeloma patients. Results from a Phase 1/2 study indicate that daratumumab may be effective and safe in heavily pretreated...
View ArticleTrends In The Use Of Stem Cell Transplantation For Multiple Myeloma (ASH 2012)
Findings from a retrospective study of stem cell transplantation among U.S. and Canadian multiple myeloma patients show that the technique has become more common in the past 15 years. In addition, the...
View ArticleShort-Term Velcade-Based Combination Therapies May Be Effective And Safe For...
Results from a recent, small-scale study conducted at the MD Anderson Cancer Center in Houston suggest that three Velcade-based combination therapies given at lower doses over a short period of time...
View ArticleTandem Auto-Allo Transplantation May Improve Prognosis Of High-Risk Myeloma...
Results from a small German study indicate that a stem cell transplant using the patient’s own cells, followed by a transplant using cells from a donor, may improve the prognosis of multiple myeloma...
View ArticleVelcade-Dexamethasone Plus Donor Lymphocyte Infusions In Myeloma Patients...
Results from a small Italian Phase 2 clinical trial indicate that Velcade plus dexamethasone, followed by donor lymphocyte infusions, may be an important treatment option for patients who relapse after...
View ArticleClik here to view.
Disease Status May Be Key To Outcome Of Second Stem Cell Transplant In...
Results of a retrospective British study add to the body of research indicating that a second stem cell transplant can be effective salvage therapy for certain relapsed multiple myeloma patients. The...
View ArticleClik here to view.
Long-Term Analysis Highlights Potential Survival Benefit Of Auto-Allo...
Long-term results from a European study indicate that an autologous stem cell transplant followed by a reduced-intensity donor transplant may lead to better survival outcomes in multiple myeloma...
View ArticlePomalyst Plus Low-Dose Dexamethasone Is Active In High-Risk Relapsed Myeloma...
A sub-analysis of recent Phase 2 clinical trial results indicates that Pomalyst in combination with low-dose dexamethasone is effective and safe in multiple myeloma patients with high-risk chromosomal...
View ArticleUpdate On Benefits And Risks Of Revlimid Maintenance Therapy (IMW 2013)
Further findings from two clinical studies of Revlimid maintenance therapy were presented at the 14th International Myeloma Workshop (IMW) in Kyoto, Japan, earlier this month. Both studies involved...
View ArticleSpanish Expert Recommends Early Treatment For High-Risk Smoldering Myeloma...
During a session at the International Myeloma Workshop (IMW) held in Japan earlier this month, Dr. María-Victoria Mateos of the University Hospital in Salamanca, Spain, discussed whether smoldering...
View ArticleKyprolis Shows Good Response Rates In Heavily Pretreated High-Risk Myeloma...
A subanalysis of recent clinical trial results shows good response rates for single-agent Kyprolis in heavily pretreated multiple myeloma patients with high-risk chromosomal abnormalities....
View ArticleNew Study Further Documents Trends In Stem Cell Transplantation For Multiple...
Findings from a recent analysis show that autologous (own) stem cell transplantation became significantly more common among North American multiple myeloma patients between 1994 and 2005. During that...
View ArticleASCO 2013 Multiple Myeloma Update – Day Three: Poster Presentations
This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday. Sunday started with a poster session in which...
View ArticleASCO 2013 Multiple Myeloma Update – Day Four: Poster Presentations
This year’s American Society of Clinical Oncology (ASCO), which was held in Chicago, began on Friday and concluded on Tuesday. Monday was the busiest day at the meeting with regard to myeloma research....
View ArticleThe European Hematology Association’s Annual Congress Starts Today: A Look At...
Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year. The first education and poster...
View ArticleA Look At The Myeloma-Related Poster Presentations At The EHA Congress (EHA...
This year’s Congress of the European Hematology Association (EHA) is currently being held in Stockholm. It started earlier this week and will run through Sunday, June 16. A substantial amount of...
View ArticleExperts Publish Treatment Recommendations For Multiple Myeloma-Related Bone...
The International Myeloma Working Group, a group of leading myeloma specialists, recently published its recommendations for the treatment of bone disease in multiple myeloma patients. The researchers...
View ArticleResearchers Develop Model To Identify Myeloma Patients With MGUS-Like Disease
Spanish researchers recently developed a new model based on a technique called multiparameter flow cytometry that can identify newly diagnosed multiple myeloma patients with disease profiles similar to...
View ArticleResearchers Assess Frequency And Prognostic Value Of Chromosomal...
French researchers recently determined that the chromosomal abnormalities t(4;14) and del(13) are less common in older newly diagnosed myeloma patients than in younger patients. In contrast, the...
View ArticleItalian Study Documents Efficacy And Safety Of Velcade Plus Dexamethasone In...
A new study provides useful, if somewhat dated, insight into the efficacy and safety of Velcade combined with dexamethasone to treat relapsed or refractory multiple myeloma. The retrospective study,...
View ArticleTransplantation With Stem Cells Collected After An Initial Transplant May...
Results from a recent study indicate that collecting more stem cells prior to a myeloma patient’s first transplant may be beneficial for future transplants. Specifically, relapsed patients who...
View ArticleResearchers Recommend Newer Methods To Assess Kidney Disease In Newly...
Findings from a recent study indicate that a newer method of determining kidney disease in multiple myeloma patients may be more accurate than traditional methods. Researchers from Greece found that...
View ArticleClik here to view.
Multiple Myeloma Survival Increased Significantly The Past 15 Years, But...
Researchers recently reported updated survival rates for multiple myeloma patients in the United States. The results show that survival has improved steadily – and markedly – from 1998 to 2009....
View ArticleKyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?
A new retrospective study provides insight into the benefit the new myeloma drugs Kyprolis and Pomalyst may provide to patients who are resistant to, or cannot tolerate, both Velcade and Revlimid....
View ArticleKyprolis-Revlimid-Dexamethasone Combination Continues To Show Promise For...
Results from a recent Phase 2 trial indicate that the combination of Kyprolis, Revlimid, and dexamethasone is effective in relapsed multiple myeloma patients. Specifically, the results show that 77...
View ArticlePomalyst-Cyclophosphamide-Prednisone Combination Effective And Safe In...
Results from a recent Italian Phase 1/2 clinical trial indicate that the combination of Pomalyst, cyclophosphamide, and prednisone is effective and safe in relapsed and refractory multiple...
View ArticleChromosomal Abnormalities May Influence Myeloma Symptoms At Diagnosis
Findings from a recent retrospective study conducted at the Mayo Clinic indicate that chromosomal abnormalities may influence which symptoms a multiple myeloma patient has at diagnosis. For...
View ArticleRespiratory Tract Infections And Shingles Linked To An Increased Risk Of...
Findings from a recent study indicate that a history of certain infections is associated with an increased risk of a person eventually developing multiple myeloma. The study is based on data for...
View ArticleStem Cell Transplantation Effective In Myeloma Patients With Advanced Kidney...
Findings from a recent retrospective study conducted at the Mayo Clinic indicate that autologous stem cell transplantation is an effective treatment option for multiple myeloma patients with...
View ArticleWhole-Body MRI Helps Identify MGUS Patients At Risk For Progression To...
Findings from a German retrospective study indicate that whole-body magnetic resonance imaging can help identify patients with monoclonal gammopathy of undetermined significance who are at increased...
View ArticleExtended Post-Transplant Treatment With Revlimid, Velcade, And Dexamethasone...
A new retrospective study by Emory University researchers may stir debate about the best way to treat high-risk myeloma patients. The researchers investigated treating high-risk myeloma patients for...
View Article
